Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to […]

Weiterlesen

Avisa Diagnostics to Participate at Upcoming Investor Events

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, announced today that […]

Weiterlesen

Avisa Diagnostics Appoints G. Michael Landis as Chief Financial Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers and […]

Weiterlesen

Avisa Diagnostics to Participate in Renmark’s Virtual Non-Deal Roadshow Series on June 17, 2021

Avisa Diagnostics Inc. (CSE: AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of bacterial load in post-COVID-19 long haulers […]

Weiterlesen

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

. – Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ – Pivotal Trials Planned in […]

Weiterlesen